Defining Rapid and Early Seizure Termination (REST) in Epilepsy
May 16th 2025A panelist discusses how REST empowers patients and caregivers to intervene at seizure onset with fast-acting rescue therapies, preventing escalation, reducing emergency care, and improving long-term outcomes and quality of life.
Recognizing Scientific Excellence and Impact in Multiple Sclerosis Research: Bruce Bebo, PhD
May 15th 2025The executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]
Advancing MS Care Through Early Intervention and Deeper CNS Insights: Jack P. Antel, MD
May 15th 2025The professor of neurology and neurosurgery at McGill University discussed the evolution of multiple sclerosis treatment, the need for earlier intervention, and the pressing scientific questions surrounding neuroinflammation. [WATCH TIME: 4 minutes]
Second-Line Treatments for CIDP
May 15th 2025Panelists discuss how treatment options for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who do not respond to intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) include second-line therapies such as plasmapheresis, corticosteroids, immunosuppressive agents, and newer options like efgartigimod, with a focus on a tailored approach to manage refractory cases effectively and improve patient outcomes.
Evaluating Efficacy and Individualizing Treatment in CIDP
May 15th 2025Panelists discuss how evaluating the efficacy of treatment in chronic inflammatory demyelinating polyneuropathy (CIDP) involves a combination of clinical, functional, and electrophysiological measures, and emphasize the importance of individualizing treatment approaches based on disease subtype, prior therapy response, comorbidities, patient preferences, and ongoing monitoring to optimize patient outcomes.
Advancing ALS Through Gene Therapies, Early Intervention, and Multidisciplinary Care: Brian Lin, PhD
May 15th 2025The research portfolio director at the Muscular Dystrophy Association discussed the evolving ALS therapeutic landscape, highlighting advances in genetic and RNA-based interventions. [WATCH TIME: 6 minutes]
The Critical Role of Dystrophin in the Pathophysiology of Duchenne Muscular Dystrophy
May 14th 2025An expert discusses the critical role of dystrophin in maintaining muscle integrity across multiple systems, explaining how its absence in Duchenne and Becker muscular dystrophy leads to widespread complications—including neurologic, pulmonary, cardiac, gastrointestinal, urinary, and orthopedic issues—driven by chronic muscle damage, inflammation, and fibrosis.
Navigating Duchenne Muscular Dystrophy: An Early-Childhood Case Example
May 14th 2025An expert discusses the evolving treatment landscape of Duchenne muscular dystrophy (DMD), highlighting advances in gene therapy, exon-skipping agents, and novel corticosteroids that aim to slow disease progression, improve muscle function, and enhance quality of life, while emphasizing the growing role of personalized medicine and early intervention in optimizing long-term outcomes.
CSAI and INFUS-ON Study for Treatment of Parkinson Disease
Panelists discuss how the recently FDA-approved SPN-830 apomorphine infusion pump demonstrated significant efficacy in reducing off time and improving motor function in the INFUS-ON study, with physicians expressing optimistic views about both the US and European clinical trial results.
Continuous Subcutaneous Apomorphine Infusion (CSAI) and TOLEDO Study in Parkinson Disease
Panelists discuss how continuous subcutaneous apomorphine infusion (CSAI) demonstrates favorable pharmacokinetics compared with other formulations, with the TOLEDO study and its extension showing significant reductions in off time and improvements in motor function with manageable safety profiles.
Insights on Quanterix Simoa Assay to Diagnose Alzheimer Disease: Mark Roskey, PhD
May 13th 2025The chief scientific officer at Quanterix gave a clinical overview on how the company’s Simoa platform enables ultrasensitive detection of neurodegeneration biomarkers in blood, transforming Alzheimer and Parkinson disease research. [WATCH TIME: 3 minutes]
A Mother’s Journey Through Diagnosis and Acceptance of Duchenne Muscular Dystrophy: Debra Miller
May 13th 2025The chief executive officer and founder at CureDuchenne shared her emotional journey from her son’s diagnosis of Duchenne to embracing a new path focused on advocacy, adaptation, and resilience. [WATCH TIME: 4 minutes]
Video: Dyskinesia and Patient Communication in Parkinson Disease
May 12th 2025Panelists discuss how early recognition of dyskinesia symptoms, ongoing patient-clinician communication, and individualized treatment strategies are key to effectively managing Parkinson disease and improving patients’ quality of life.
Continuous Dosing of Lecanemab for Alzheimer’s Disease
May 12th 2025Panelists discuss how long-term data from the Clarity AD OLE study support lecanemab as an effective maintenance therapy for early Alzheimer’s disease, with reduced infusion frequency improving patient and caregiver quality of life, while potentially delaying disease progression and enhancing long-term cognitive and functional outcomes.
Clarity-AD-OLE Study in Alzheimer’s Disease
May 12th 2025Panelists discuss how interim results from the Clarity AD open-label extension demonstrate that lecanemab provides sustained cognitive and functional benefits with a stable safety profile over time, reinforcing the value of early initiation and continuous treatment in Alzheimer’s disease management.
Clinical Data With Foscarbidopa/Foslevodopa CSCI in Parkinson Disease
May 9th 2025Panelists discuss how phase 3 clinical trials demonstrated the efficacy, safety, and quality of life improvements associated with continuous subcutaneous foscarbidopa/foslevodopa in both short-term and long-term studies.
Optimizing Benzodiazepine Use for Breakthrough Seizures in Epilepsy
May 9th 2025A panelist discusses how selecting the optimal benzodiazepine rescue medication depends on factors such as route of administration, setting, and patient preference, with intranasal formulations increasingly favored for their rapid onset, ease of use, and greater acceptance in outpatient and home environments.